"Near Cure" treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct

Cell Immunol. 2022 Aug:378:104561. doi: 10.1016/j.cellimm.2022.104561. Epub 2022 Jun 11.

Abstract

Our previous studies demonstrated increased serum levels of macrophage migration inhibitory factor (MIF-1) and its homologue, MIF-2, in males during MS progression; and that genetically high-MIF-expressing male subjects with relapsing multiple sclerosis (MS) had a significantly greater risk of conversion to progressive MS than lower-MIF-expressing males and females. However, female MS subjects with severe disease expressed higher levels of CD74, the common MIF-1/MIF-2 receptor, on blood cells. In the murine model of MS, experimental autoimmune encephalomyelitis (EAE), both male and female mice lacking MIF-1 and/or MIF-2 were clinically improved during development of moderately severe disease, thus implicating both homologs as co-pathogenic contributors. The current study using MIF-deficient mice with severe acute EAE revealed a highly significant reduction of EAE scores in MIF-1-deficient females, in contrast to only minor and delayed reduction of clinical signs in MIF-1-deficient males. However, clinical EAE scores and factor expression were strongly suppressed in males and further reduced in females after treatment of WT and MIF-1-, MIF-2- and MIF-1/2-DUAL-deficient female and male mice with a MHCII DRα1-MOG-35-55 molecular construct that competitively inhibits MIF-1 & MIF-2 signaling through CD74 as well as T cell activation. These results suggest sex-dependent differences in which the absence of the MIF-1 and/or MIF-2 genotypes may permit stronger compensatory CD74-dependent EAE-inducing responses in males than in females. However, EAE severity in both sexes could still be reduced nearly to background (a "near cure") with DRα1-MOG-35-55 blockade of compensatory MIF and CD74-dependent factors known to attract peripheral inflammatory cells into the spinal cord tissue.

Keywords: Central nervous system (CNS); Cytokines/chemokines; DRα1-MOG-35-55 construct, CD74; Eperimental autoimmune encephalomyelitis (EAE); Inflammation; Macrophage migration inhibitory factors (MIF-1 & MIF-2); Multiple sclerosis (MS); Sex differences.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Encephalomyelitis, Autoimmune, Experimental*
  • Female
  • Histocompatibility Antigens Class II / immunology
  • Humans
  • Intramolecular Oxidoreductases / genetics
  • Intramolecular Oxidoreductases / metabolism
  • MSH Release-Inhibiting Hormone* / metabolism
  • MSH Release-Inhibiting Hormone* / therapeutic use
  • Macrophage Migration-Inhibitory Factors* / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Multiple Sclerosis*
  • Spinal Cord

Substances

  • Histocompatibility Antigens Class II
  • Macrophage Migration-Inhibitory Factors
  • MSH Release-Inhibiting Hormone
  • Intramolecular Oxidoreductases
  • MIF protein, human